Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 5/1 cls
Celgene Corp. (NASDAQ:CELG) JMP Securities Charles Duncan Price target Market outperform -1% $39.54
Duncan lowered his target to $73 from $78 and his FY10 non-GAAP EPS estimate to $2.38 from $2.58. He also reduced his FY09 and FY10 revenue estimates to $2.6B from $2.7B and to $3.0B from $3.1B, respectively. He said the adjusted model will "account for new economic realities that are impacting demand

Read the full 785 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers